Chemical: Drug
voriconazole

Available Prescribing Info

Dosing Guidelines
  1. Annotation of CPIC Guideline for voriconazole and CYP2C19
  2. Annotation of DPWG Guideline for voriconazole and CYP2C19
last updated 03/15/2017

1. Annotation of CPIC Guideline for voriconazole and CYP2C19

Summary

The CPIC dosing guideline for voriconazole recommends selecting an alternative agent that is not dependent on CYP2C19 metabolism in adults who are CYP2C19 ultrarapid metabolizers, rapid metabolizers or poor metabolizers. In pediatric patients, an alternative agent should be used in patients who are ultrarapid metabolizers or poor metabolizers. In pediatric rapid metabolizers, therapy should be initiated at recommended standard case dosing, then therapeutic dosing monitoring should be used to titrate dose to therapeutic trough concentrations.

Annotation

This annotation is based on the CPIC® guideline for voriconazole and CYP2C19.

December 2016

Table 1: Dosing recommendations for voriconazole treatment based on CYP2C19 phenotype for adult patients

Adapted from Tables 1 and 2 of the 2016 guideline manuscript.

Likely PhenotypeGenotypesbExamples of diplotypesImplications for pharmacologic measuresTherapeutic recommendationsClassification of Recommendationse
Ultrarapid metabolizer (~2-5% of patients)aAn individual carrying two increased function alleles*17/*17In patients for whom an ultrarapid metabolizer genotype is identified, the probability of attainment of therapeutic voriconazole concentrations is small with standard dosing.Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.fModerateg
Rapid metabolizer (~2-30% of patients)aAn individual carrying one normal function allele and one increased function allele*1/*17In patients for whom a rapid metabolizer genotype is identified, the probability of attainment of therapeutic concentrations is modest with standard dosing.Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.fModerate
Normal metabolizerc (~35-50% of patients)aAn individual carrying two normal function alleles*1/*1Normal voriconazole metabolismInitiate therapy with recommended standard of care dosing.fStrong
Intermediate metabolizer (~18-45% of patients)aAn individual carrying one normal function allele and one no function allele or one no function allele and one increased function allele*1/*2, *1/*3, *2/*17dHigher dose-adjusted trough concentrations of voriconazole compared to normal metabolizers.Initiate therapy with recommended standard of care dosing.fModerate
Poor metabolizer (~2-15% of patients)aAn individual carrying two no function alleles*2/*2, *2/*3, *3/*3Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events.Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.f In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.Moderate

a See the CYP2C19 Frequency Table for race specific allele and phenotype frequencies.

b Assignment of allele function can be found on PharmGKB (CYP2C19 Allele Definition Table) and citations for allele function can be on PharmGKB (CYP2C19 Allele Functionality Table).

c Based on the CPIC term standardization project, the term "Normal Metabolizer" will be used instead of the term "Extensive Metabolizer" in all new and updated CPIC guidelines.

d The predicted metabolizer phenotype for the *2/*17 genotype is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the no function CYP2C19*2 (Sibbing et al., 2010). See the 2016 Supplement for a more comprehensive list of predicted metabolizer phenotypes.

e Rating scheme is described in the 2016 Supplement

f Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, TDM, and comorbidities.

g Recommendations based upon data extrapolated from patients with CYP2C19*1/*17 genotype

Table 2: Dosing recommendations for voriconazole treatment based on CYP2C19 phenotype for pediatric patients

Adapted from Tables 1 and 3 of the 2016 guideline manuscript.

Likely PhenotypeGenotypesbExamples of diplotypesImplications for pharmacologic measuresTherapeutic recommendationsClassification of Recommendationse
Ultrarapid metabolizer (~2-5% of patients)aAn individual carrying two increased function alleles*17/*17In patients for whom an ultrarapid metabolizer genotype is identified, the probability of attainment of therapeutic voriconazole concentrations is small.Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.f,gModerate
Rapid metabolizer (~2-30% of patients)aAn individual carrying one normal function allele and one increased function allele*1/*17In patients for whom a rapid metabolizer genotype is identified, the probability of attainment of therapeutic concentrations is variable.Initiate therapy with recommended standard case dosing.f Use therapeutic dose monitoring to titrate dose to therapeutic trough concentrations.g,hModerate
Normal metabolizerc (~35-50% of patients)aAn individual carrying two normal function alleles*1/*1Normal voriconazole metabolismInitiate therapy with recommended standard of care dosing.fStrong
Intermediate metabolizer (~18-45% of patients)aAn individual carrying one normal function allele and one no function allele or one no function allele and one increased function allele*1/*2, *1/*3, *2/*17dHigher dose-adjusted trough concentrations of voriconazole compared to normal metabolizers.Initiate therapy with recommended standard of care dosing.fModerate
Poor metabolizer (~2-15% of patients)aAn individual carrying two no function alleles*2/*2, *2/*3, *3/*3Higher dose-adjusted trough concentrations of voriconazole and may increase probability of adverse events.Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazolef,i. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.Moderatei

a See the CYP2C19 frequency table for race specific allele and phenotype frequencies.

b Assignment of allele function can be found on PharmGKB (CYP2C19 Allele Definition Table) and citations for allele function can be on PharmGKB (CYP2C19 Allele Functionality Table).

c Based on the CPIC term standardization project, the term "Normal Metabolizer" will be used instead of the term "Extensive Metabolizer" in all new and updated CPIC guidelines.

d The predicted metabolizer phenotype for the *2/*17 genotype is a provisional classification. The currently available evidence indicates that the CYP2C19*17 increased function allele is unable to completely compensate for the no function CYP2C19*2 (Sibbing et al., 2010). See the 2016 Supplement for a more comprehensive list of predicted metabolizer phenotypes.

e Rating scheme is described in the 2016 Supplement

f Further dose adjustments or selection of alternative therapy may be necessary due to other clinical factors, such as drug interactions, hepatic function, renal function, species, site of infection, TDM, and comorbidities.

g Achieving voriconazole therapeutic concentrations in the pediatric population with ultrarapid and rapid metabolizer phenotypes in a timely manner is difficult. As critical time may be lost in achieving therapeutic concentrations, an alternative antifungal agent is recommended in order that the child receives effective antifungal therapy as soon as possible.

h Meticulous therapeutic drug monitoring is critical for rapid metabolizers. There is insufficient evidence to distinguish a CYP2C19*1/*17 and *1/*1 pediatric patient due to large variability in trough concentrations.

i Recommendation based upon data extrapolated from adults.

last updated 08/10/2011

2. Annotation of DPWG Guideline for voriconazole and CYP2C19

Summary

Monitor voriconazole serum concentration for CYP2C19 poor and intermediate metabolizers.

Annotation

The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for voriconazole based on CYP2C19 genotype [Article:21412232]. They conclude to monitor serum concentration for patients carrying the CYP2C19 PM or IM phenotype.

Phenotype (Genotype)Therapeutic Dose RecommendationLevel of EvidenceClinical Relevance
CYP2C19 PM (*2/*2, *2/*3, *3/*3)Monitor serum concentrationPublished controlled studies of moderate quality* relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpointsMinor clinical effect (statistically significant difference): QTc prolongation (<450 ms female, <470 ms male); international normalized ratio increase < 4.5 ; Kinetic effect (statistically significant difference)
CYP2C19 IM (*1/*2, *1/*3, *17/*2, *17/*3)Monitor serum concentrationPublished controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpointsMinor clinical effect (statistically significant difference): QTc prolongation (<450 ms female, <470 ms male); international normalized ratio increase < 4.5 ; Kinetic effect (statistically significant difference)
CYP2C19 UM (*17/*17)NonePublished controlled studies of moderate quality# relating to phenotyped and/or genotyped patients or healthy volunteers, and having relevant pharmacokinetic or clinical endpointsMinor clinical effect (statistically significant difference): QTc prolongation (<450 ms female, <470 ms male); international normalized ratio increase < 4.5 ; Kinetic effect (statistically significant difference)

Annotated Labels

  1. Annotation of FDA Label for voriconazole and CYP2C19
  2. Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4
  3. Annotation of PMDA Label for voriconazole and CYP2C19
  4. Annotation of HCSC Label for voriconazole and CYP2C19
last updated 10/25/2013

1. Annotation of FDA Label for voriconazole and CYP2C19

On FDA Biomarker List
Actionable PGx

Summary

Voriconazole is an antifungal used to treat serious infections of Aspergillus fumigatu, Candida, Scedosporium, Fusarium and other species. Voriconazole is metabolized in the liver by CYP2C19, CYP2C9 and CYP3A4. It also influences expression of metabolizing enzymes and interacts with several other drugs.

There's more of this label. Read more.

last updated 08/06/2014

2. Annotation of EMA Label for voriconazole and CYP2C19,CYP2C9,CYP3A4

Informative PGx

Summary

The EMA European Public Assessment Report (EPAR) for voriconazole (VFEND) does not contain pharmacogenetic information. It contains warning information regarding the co-administration of drugs that are substrates, inhibitors or activators of CYP3A4, CYP2C9 or CYP2C19 due to drug-drug interactions.

There's more of this label. Read more.

3. Annotation of PMDA Label for voriconazole and CYP2C19

Actionable PGx

Summary

The PMDA package insert for voriconazole (VFEND) notes that it is metabolized by CYP2C19 (as well as CYP2C9 and CYP3A4) and provides tables showing the difference in pharmacokinetic metrics between extensive metabolizers (EM), intermediate metabolizers (also known as heterozygous extensive metabolizers (HEM)) and poor metabolizers (PM) in adults and pediatrics.

There's more of this label. Read more.

4. Annotation of HCSC Label for voriconazole and CYP2C19

Actionable PGx

Summary

The product monograph for voriconazole notes that CYP2C19 poor metabolizers have, on average, 4-fold higher exposure to the drug as compared to extensive metabolizers. However, the product monograph does not make any statements regarding genetic testing of CYP2C19 prior to treatment.

There's more of this label. Read more.

Clinical Variants that meet the highest level of criteria, manually curated by PharmGKB, are shown below.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for voriconazole

Gene ? Variant?
(147) 		Alternate Names ? Chemicals ? Alleles ?
(+ chr strand) 		Function ? Amino Acid?
Translation
No VIP available CA VA CYP2C19 *1 N/A N/A N/A
No VIP available CA VA CYP2C19 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2A N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2B N/A N/A N/A
No VIP available CA VA CYP2C19 *3 N/A N/A N/A
No VIP available CA VA CYP2C19 *17 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *3 N/A N/A N/A
No VIP available No VIP available VA CYP3A5 *3A N/A N/A N/A
No VIP available CA VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
 SNP
I1145I
No VIP available CA VA
rs4646437 NC_000007.13:g.99365083G>A, NC_000007.14:g.99767460G>A, NG_008421.1:g.21726C>T, NM_001202855.2:c.671-205C>T, NM_017460.5:c.671-202C>T, XM_011515841.1:c.671-202C>T, XM_011515842.1:c.671-205C>T, rs386594232, rs57997883
G > A
 SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • VCZ
  • voriconazole
Trade Names
  • Vfend
Brand Mixture Names

PharmGKB Accession Id

PA10233

Type(s):

Drug

Description

Voriconazole (Vfend®, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections.

Source: Drug Bank

Indication

For the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by _Scedosporium apiospermum_ and _Fusarium_ spp.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Voriconazole binds and inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-alpha sterol demethylase. The inhibition of 14-alpha sterol demethylase results in a depletion of ergosterol in fungal cell membrane.

Source: Drug Bank

Pharmacology

Voriconazole is a triazole antifungal agent indicated for use in the treatment of fungal infections including invasive aspergillosis, esophageal candidiasis, and serious fungal infections caused by _Scedosporium apiospermum_ (asexual form of _Pseudallescheria boydii_) and _Fusarium_ spp. including _Fusarium solani_. Fungal plasma membranes are similar to mammalian plasma membranes, differing in having the nonpolar sterol ergosterol, rather than cholesterol, as the principal sterol. Membrane sterols such as ergosterol provide structure, modulation of membrane fluidity, and possibly control of some physiologic events. Voriconazole effects the formation of the fungal plasma membrane by indirectly inhibiting the biosynthesis of ergosterol. This results in plasma membrane permeability changes and inhibition of growth.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic. The major metabolite of voriconazole is the N-oxide, which accounts for 72% of the circulating radiolabelled metabolites in plasma. Since this metabolite has minimal antifungal activity, it does not contribute to the overall efficacy of voriconazole.

Source: Drug Bank

Protein Binding

58%

Source: Drug Bank

Absorption

The oral bioavailability is estimated to be 96% (CV 13%).

Source: Drug Bank

Toxicity

The minimum lethal oral dose in mice and rats was 300 mg/kg (equivalent to 4 and 7 times the recommended maintenance dose (RMD), based on body surface area). At this dose, clinical signs observed in both mice and rats included salivation, mydriasis, titubation (loss of balance while moving), depressed behavior, prostration, partially closed eyes, and dyspnea. Other signs in mice were convulsions, corneal opacification and swollen abdomen.

Source: Drug Bank

Route of Elimination

Voriconazole is eliminated via hepatic metabolism with less than 2% of the dose excreted unchanged in the urine.

Source: Drug Bank

Volume of Distribution

* 4.6 L/kg

Source: Drug Bank

Chemical Properties

Chemical Formula

C16H14F3N5O

Source: Drug Bank

Average Molecular Weight

349.3105

Source: Drug Bank

Monoisotopic Molecular Weight

349.11504471

Source: Drug Bank

SMILES

C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O

Source: PubChem

InChI String

InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1

Source: PubChem

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Voriconazole Pathway, Pharmacokinetics
    Pathway describing the metabolism of voriconazole

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

EvidenceGene
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
ABCB1
DG DL CA VA No VIP available No VIP available
CYP2C19
No Dosing Guideline available DL No Clinical Annotation available VA No VIP available No VIP available
CYP2C9
No Dosing Guideline available DL CA VA No VIP available No VIP available
CYP3A4
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP3A5

Drug Targets

Gene Description
CYP51A1 (source: Drug Bank )

Drug Interactions

Interaction Description
alprazolam - voriconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank )
alprazolam - voriconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank )
astemizole - voriconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
astemizole - voriconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
bosentan - voriconazole This imidazole increases the effect and toxicity of bosentan (source: Drug Bank )
bosentan - voriconazole This imidazole increases the effect and toxicity of bosentan (source: Drug Bank )
bromazepam - voriconazole Voriconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
carbamazepine - voriconazole Decreases the effect of voriconazole (source: Drug Bank )
carbamazepine - voriconazole Decreases the effect of voriconazole (source: Drug Bank )
chlordiazepoxide - voriconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank )
chlordiazepoxide - voriconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank )
cisapride - voriconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
cisapride - voriconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
clonazepam - voriconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank )
clonazepam - voriconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank )
clorazepate - voriconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank )
cyclosporine - voriconazole Voriconazole increases the effect and toxicity of cyclosporine (source: Drug Bank )
cyclosporine - voriconazole Voriconazole increases the effect and toxicity of cyclosporine (source: Drug Bank )
dantrolene - voriconazole Voriconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
diazepam - voriconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank )
diazepam - voriconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank )
dihydroergotamine - voriconazole Voriconazole increases the effect and toxicity of ergot derivative (source: Drug Bank )
dihydroergotamine - voriconazole Voriconazole increases the effect and toxicity of ergot derivative (source: Drug Bank )
ergotamine - voriconazole Voriconazole increases the effect and toxicity of ergot derivative (source: Drug Bank )
ergotamine - voriconazole Voriconazole increases the effect and toxicity of ergot derivative (source: Drug Bank )
estazolam - voriconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank )
estazolam - voriconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank )
fentanyl - voriconazole The imidazole increases levels/toxicity of fentanyl (source: Drug Bank )
flurazepam - voriconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank )
flurazepam - voriconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank )
fosphenytoin - voriconazole The hydantoin decreases the effect of voriconazole (source: Drug Bank )
meloxicam - voriconazole Voriconazole may increase the serum concentration of meloxicam by decreasing its metabolism via CYP2C9 and CYP3A4. Monitor for changes in the therapeutic and adverse effects of meloxicam if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
midazolam - voriconazole The imidazole increases the effect of benzodiazepine (source: Drug Bank )
midazolam - voriconazole The imidazole increases the effect of benzodiazepine (source: Drug Bank )
omeprazole - voriconazole Voriconazole increases the effect and toxicity of omeprazole (source: Drug Bank )
omeprazole - voriconazole Voriconazole increases the effect and toxicity of omeprazole (source: Drug Bank )
phenobarbital - voriconazole The barbiturate decreases the effect of voriconazole (source: Drug Bank )
phenobarbital - voriconazole The barbiturate, phenobarbital, decreases the effect of voriconazole. (source: Drug Bank )
phenytoin - voriconazole The hydantoin decreases the effect of voriconazole (source: Drug Bank )
phenytoin - voriconazole The hydantoin decreases the effect of voriconazole (source: Drug Bank )
pimozide - voriconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
pimozide - voriconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
primidone - voriconazole The barbiturate decreases the effect of voriconazole (source: Drug Bank )
primidone - voriconazole The barbiturate, primidone, decreases the effect of voriconazole. (source: Drug Bank )
quinidine - voriconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
quinidine - voriconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
ranolazine - voriconazole Increased levels of ranolazine - risk of toxicity (source: Drug Bank )
rifabutin - voriconazole Rifabutin decreases the effect of voriconazole (source: Drug Bank )
rifabutin - voriconazole Rifabutin decreases the effect of voriconazole (source: Drug Bank )
rifampin - voriconazole Rifampin decreases the effect of voriconazole (source: Drug Bank )
rifampin - voriconazole Rifampin decreases the effect of voriconazole (source: Drug Bank )
tadalafil - voriconazole Voriconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity. (source: Drug Bank )
tamoxifen - voriconazole Voriconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank )
tamoxifen - voriconazole Voriconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen. (source: Drug Bank )
tamsulosin - voriconazole Voriconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Voriconazole is initiated, discontinued, or dose changed. (source: Drug Bank )
tamsulosin - voriconazole Voriconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Voriconazole is initiated, discontinued, or dose changed. (source: Drug Bank )
telithromycin - voriconazole Voriconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects. (source: Drug Bank )
teniposide - voriconazole The strong CYP3A4 inhibitor, Voriconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
terfenadine - voriconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
terfenadine - voriconazole Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
thiothixene - voriconazole May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank )
thiothixene - voriconazole May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank )
tiagabine - voriconazole The strong CYP3A4 inhibitor, Voriconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
tipranavir - voriconazole Tipranavir may alter the serum concentration of Voriconazole. (source: Drug Bank )
tolbutamide - voriconazole Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Voriconazole. Consider alternate therapy or monitor for changes in Voriconazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. (source: Drug Bank )
tolbutamide - voriconazole Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Voriconazole. Consider alternate therapy or monitor for changes in Voriconazole therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. (source: Drug Bank )
tolterodine - voriconazole Voriconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity. (source: Drug Bank )
tolterodine - voriconazole Voriconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity. (source: Drug Bank )
toremifene - voriconazole Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank )
tramadol - voriconazole Voriconzole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. (source: Drug Bank )
trazodone - voriconazole The CYP3A4 inhibitor, Voriconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
trazodone - voriconazole The CYP3A4 inhibitor, Voriconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
triazolam - voriconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank )
triazolam - voriconazole The imidazole increases the effect of the benzodiazepine (source: Drug Bank )
trimipramine - voriconazole Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Voriconazole, a strong CYP3A4 inhibitor, may also decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Concomitant therapy should be used with caution. (source: Drug Bank )
vardenafil - voriconazole Voriconazole, a strong CYP3A4 inhibitor, may reduce the metabolism and clearance of Vardenafil. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of Vardenafil. (source: Drug Bank )
venlafaxine - voriconazole Voriconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Voriconazole is initiated, discontinued, or dose changed. (source: Drug Bank )
verapamil - voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
vincristine - voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
vinorelbine - voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - abarelix Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - alfentanil Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of alfentanil by decreasing its metabolism. Monitor for increased anesthetic and respiratory depressant effects and consider using lower alfentanil doses or alternate anesthetic. (source: Drug Bank )
voriconazole - alfuzosin Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of alfuzosin by decreasing its metabolism. Use of alfuzosin with strong CYP3A4 inhibitors is contraindicated by the manufacturer. (source: Drug Bank )
voriconazole - almotriptan Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of almotriptan by decreasing its metabolism. The initial and maximum doses should not exceed 6.25 mg and 12.5 mg, respectively during concomitant therapy. Concomitant therapy should be avoided in patients with impaired hepatic or renal function. (source: Drug Bank )
voriconazole - alprazolam Voriconazole may increase the serum concentration of alprazolam by decreasing its metabolism. Monitor for alprazolam toxicity if voriconazole is initiated or dose increased. (source: Drug Bank )
voriconazole - amiodarone Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of amiodarone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of amiodarone if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - amitriptyline Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - amlodipine Voriconazole may increase the serum concentration of amlodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of amlodipine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - amobarbital Amobarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated. (source: Drug Bank )
voriconazole - amoxapine Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - amprenavir Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of amprenavir by decreasing its metabolism. The serum concentration of voriconazole may be increased by amprenavir. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed. (source: Drug Bank )
voriconazole - apomorphine Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - aprepitant Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of aprepitant by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of aprepitant if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - aripiprazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of aripiprazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of aripiprazole if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - atazanavir Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of atazanavir by decreasing its metabolism. The serum concentration of voriconazole may be increased by atazanavir. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed. (source: Drug Bank )
voriconazole - atorvastatin Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of atorvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - benzphetamine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of benzphetamine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of benzphetamine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - bisoprolol Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bisoprolol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bisoprolol if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - bortezomib Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bortezomib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bortezomib if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - bosentan Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bosentan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bosentan if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - bromazepam Voriconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for bromazepam toxicity if voriconazole is initiated or dose increased. (source: Drug Bank )
voriconazole - bromocriptine Voriconazole may increase the serum concentration of bromocriptine likely by decreasing its metabolism. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - budesonide Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of budesonide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of budesonide if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - buprenorphine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of buprenorphine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of buprenorphine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - buspirone Voriconazole may increase the serum concentration of buspirone likely by decreasing its metabolism via CYP3A4. Monitor for changes in the therapeutic and adverse effects of buspirone if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - busulfan Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of busulfan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of busulfan if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - butabarbital Butabarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated. (source: Drug Bank )
voriconazole - butalbital Butalbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated. (source: Drug Bank )
voriconazole - cabergoline Voriconazole may increase the serum concentration of cabergoline likely by decreasing its metabolism. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - calcitriol Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of calcitriol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of calcitriol if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - capecitabine Capecitabine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if capecitabine is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - carbamazepine Carbamazepine may reduce serum concentrations and efficacy of voriconazole likely by increasing its metabolism. Concomitant voriconazole and carbamazepine therapy is contraindicated. (source: Drug Bank )
voriconazole - chlordiazepoxide Voriconazole may increase the serum concentration of chlordiazepoxide by decreasing its metabolism. Monitor for chlordiazepoxide toxicity if voriconazole is initiated or dose increased. (source: Drug Bank )
voriconazole - chloroquine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of chloroquine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of chloroquine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - chlorpheniramine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of chlorpheniramine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of chlorpheniramine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - chlorpropamide Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - ciclesonide Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ciclesonide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ciclesonide if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - cilostazol Voriconzole may increase the serum concentration of cilostazol by decreasing its metabolism. Monitor for increased therapeutic/adverse effects of cilostazol and consider reducing the dose during concomitant therapy. (source: Drug Bank )
voriconazole - cinacalcet Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cinacalcet by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cinacalcet if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - cisapride Voriconazole may increase the serum concentration and toxicity of cisapride likely by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - citalopram Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of citalopram by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of citalopram if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - clarithromycin Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of clarithromycin by decreasing its metabolism. Clarithromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - clobazam Voriconazole may increase the serum concentration of clobazam by decreasing its metabolism. Monitor for clobazam toxicity if voriconazole is initiated or dose increased. (source: Drug Bank )
voriconazole - clomipramine Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - clonazepam Voriconazole may increase the serum concentration of clonazepam by decreasing its metabolism. Monitor for clonazepam toxicity if voriconazole is initiated or dose increased. (source: Drug Bank )
voriconazole - clorazepate Voriconazole may increase the serum concentration of clorazepate by decreasing its metabolism. Monitor for clorazepate toxicity if voriconazole is initiated or dose increased. (source: Drug Bank )
voriconazole - cocaine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cocaine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cocaine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - colchicine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of colchicine by decreasing its metabolism. A dose reduction of colchicine is recommended along with increased monitoring for colchicine toxicity. Concomitant therapy is contraindicated in patients with renal and/or hepatic impairment. (source: Drug Bank )
voriconazole - conivaptan Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of conivaptan by inhibiting its metabolism. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - cyclosporine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of cyclosporine by decreasing its metabolism. Consider reducing the dose of cyclosporine. Monitor cyclosporine serum concentrations and therapeutic and toxic effects if initiating, discontinuing or adjusting voriconazole therapy. (source: Drug Bank )
voriconazole - dantrolene Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dantrolene by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of dantrolene if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - dapsone Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dapsone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of dapsone if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - darifenacin Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of darifenacin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of darifenacin if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - darunavir Darunavir may reduce serum concentrations and efficacy of voriconazole. This combination should be avoided unless the potential benefits outweigh the risk of reduced voriconazole efficacy. (source: Drug Bank )
voriconazole - dasatinib Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of dasatinib by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dasatinib if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - delavirdine Delavirdine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if delavirdine is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - desipramine Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - dexamethasone Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dexamethasone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of dexamethasone if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - diazepam Voriconazole may increase the serum concentration of diazepam by decreasing its metabolism. Monitor for diazepam toxicity if voriconazole is initiated or dose increased. (source: Drug Bank )
voriconazole - diclofenac Voriconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of diclofenac by decreasing its metabolism. Renal impairment may increase the risk of diclofenac adverse effects. Monitor for changes in therapeutic and adverse effects of diclofenac if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - didanosine Didanosine may interfere with the absorption of orally administered voriconazole. Enteric coated didanosine does not exert this effect. Didanosine buffered formulations should be administered at least 2 hours from oral voriconazole administration. (source: Drug Bank )
voriconazole - digitoxin Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of digitoxin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of digitoxin if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - digoxin Voriconazole may increase the serum concentration of digoxin. Monitor for increased serum concentrations and toxic effects of digoxin if voriconazole is initiated or dose increased. (source: Drug Bank )
voriconazole - dihydroergotamine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of dihydroergotamine by decreasing its metabolism. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - diltiazem Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of diltiazem by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of diltiazem if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - disopyramide Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of disopyramide by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of disopyramide if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - docetaxel Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of docetaxel by decreasing its metabolism. Consider using a non-interacting antifungal or monitor for changes in the therapeutic and adverse effects of docetaxel if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - dofetilide Voriconazole may increase the serum concentration of dofetilide by decreasing its metabolism. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - dolasetron Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - doxepin Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of doxepin by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of doxepin if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - doxorubicin Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of doxorubicin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of doxorubicin if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - dronedarone Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - droperidol Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - efavirenz Efavirenze may decrease the serum concentration of voriconazole likely by increasing its metabolism. Voriconazole may increase the serum concentration of efavirenz by decreasing its metabolism. Consider alternate therapy or adjust doses and monitor for reduced voriconazole efficacy and increased efavirenz adverse effects during concomitant therapy. (source: Drug Bank )
voriconazole - eletriptan Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eletriptan by decreasing its metabolism. Consider avoiding administration of the two agents within 72 hours of each other. Monitor for changes in the therapeutic and adverse effects of eletriptan if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - eplerenone Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eplerenone by decreasing its metabolism. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - ergonovine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergonovine by decreasing its metabolism. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - ergotamine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ergotamine by decreasing its metabolism. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - erlotinib Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of erlotinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of erlotinib if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - erythromycin Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of erythromycin by decreasing its metabolism. Erythromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - escitalopram Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of escitalopram by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of escitalopram if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - estazolam Voriconazole may increase the serum concentration of estazolam by decreasing its metabolism. Monitor for estazolam toxicity if voriconazole is initiated or dose increased. (source: Drug Bank )
voriconazole - eszopiclone Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of eszopiclone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of eszopiclone if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - ethosuximide Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ethosuximide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ambrisentan if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - etoposide Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of etoposide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of etoposide if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - everolimus Voriconzole, a strong CYP3A4 inhibitor, may increase the serum concentration of everolimus by decreasing its metabolism. Concurrent therapy should be avoided. (source: Drug Bank )
voriconazole - felbamate Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of felbamate by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of felbamate if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - felodipine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of felodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of felodipine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - fentanyl Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of fentanyl by decreasing its metabolism. Adverse effects include life-threatening respiratory depression. Monitor for changes in the therapeutic and adverse effects of fentanyl if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - flecainide Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - floxuridine Floxuridine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if floxuridine is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - fluconazole Fluconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of voriconazole if fluconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - flunisolide Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flunisolide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of flunisolide if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - fluorouracil Fluorouracil, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if fluorouracil is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - fluoxetine Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - flupenthixol Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - flurazepam Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flurazepam by decreasing its metabolism. Monitor for flurazepam toxicity if voriconazole is initiated or dose increased. (source: Drug Bank )
voriconazole - flurbiprofen Flurbiprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if flurbiprofen is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - flutamide Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of flutamide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of flutamide if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - fosamprenavir Voriconazole may increase the serum concentration of fosamprenavir by decreasing its metabolism. Fosamprenavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed. (source: Drug Bank )
voriconazole - foscarnet Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - gatifloxacin Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - gefitinib Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of gefitinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of gefitinib if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - gemfibrozil Gemfibrozil, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if gemfibrozil is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - halofantrine Voriconazole may increase the serum concentration of halofantrine by decreasing its metabolism by CYP3A4. Concomitant therapy should be avoided due to the concentration-dependent risk of QTc prolongation related to halofantrine. (source: Drug Bank )
voriconazole - haloperidol Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of haloperidol by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of haloperidol if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - ibuprofen Ibuprofen, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if ibuprofen is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - ibutilide Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - ifosfamide Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ifosfamide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ifosfamide if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - imatinib Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of imatinib by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of imatinib if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - imipramine Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - indapamide Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - indinavir Voriconazole may increase the serum concentration of indinavir by decreasing its metabolism. Indinavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed. (source: Drug Bank )
voriconazole - indomethacin Indomethacin, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if indomethacin is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - irinotecan Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of irinotecan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of irinotecan if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - isradipine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of isradipine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of isradipine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - Ixabepilone Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ixabepilone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ixabepilone if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - ketamine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ketamine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of ketamine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - ketoconazole Ketoconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if ketoconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - lapatinib Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lapatinib by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lapatinib if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - levofloxacin Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - lidocaine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lidocaine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lidocaine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - lopinavir Lopinavir may reduce serum concentration and efficacy of voriconazole. This combination should be avoided unless the potential benefits outweigh the risk of reduced voriconazole efficacy. (source: Drug Bank )
voriconazole - lovastatin Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - loxapine Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - maprotiline Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - maraviroc Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of maraviroc by decreasing its metabolism. A dose reduction in maraviroc is warranted. Monitor for changes in the therapeutic and adverse effects of maraviroc if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - mefloquine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of mefloquine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of mefloquine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - mesoridazine Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - methadone Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of methadone by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of methadone if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - methotrimeprazine Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - methylergonovine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of methylergonovine by decreasing its metabolism. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - miconazole Miconazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if miconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - midazolam Voriconazole may increase the serum concentration of midazolam by decreasing its metabolism. Monitor for midazolam toxicity if voriconazole is initiated or dose increased. (source: Drug Bank )
voriconazole - mirtazapine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of mirtazapine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of mirtazapine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - modafinil Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of modafinil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of modafinil if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - moricizine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of moricizine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of moricizine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - moxifloxacin Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - nateglinide Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nateglinide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nateglinide if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - nefazodone Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nefazodone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nefazodone if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - nelfinavir Nelfinavir may decrease the serum concentration of voriconazole likely by increasing its metabolism. Voriconazole may increase the serum concentration of nelfinavir by decreasing its metabolism. Consider alternate therapy or adjust doses and monitor for reduced voriconazole efficacy and increased nelfinavir adverse effects during concomitant therapy. (source: Drug Bank )
voriconazole - nicardipine Nicardipine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nicardipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole and nicardipine if concomitant therapy is initiated, discontinued or doses are changed. (source: Drug Bank )
voriconazole - nifedipine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nifedipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nifedipine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - nilotinib Voriconazole may increase the serum concentration of nilotinib by inhibiting its metabolism by CYP3A4. Additive QTc prolongation may also occur. Concomitant therapy should be avoided. (source: Drug Bank )
voriconazole - nimodipine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nimodipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nimodipine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - nisoldipine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nisoldipine by decreasing its metabolism. Concomitant therapy should be avoided. (source: Drug Bank )
voriconazole - nitrendipine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of nitrendipine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of nitrendipine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - norfloxacin Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - nortriptyline Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - octreotide Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - paclitaxel Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of paclitaxel by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of paclitaxel if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - pentamidine Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - perflutren Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - pergolide Voriconazole may increase the serum concentration of pergolide likely by decreasing its metabolism. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - phencyclidine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of phencyclidine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of phencyclidine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - phenobarbital Phenobarbital may reduce serum concentrations and efficacy of voriconazole. Concomitant voriconazole and long-acting barbiturates therapy is contraindicated. (source: Drug Bank )
voriconazole - phenytoin Voriconazole may increase the serum concentration of phenytoin by decreasing its metabolism. Phenytoin may increase the serum concentration of voriconazole by increasing its metabolism. Consider alternate antifungal therapy or monitor for voriconazole therapy failure and phenytoin toxicity. (source: Drug Bank )
voriconazole - pimozide Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of pimozide by decreasing its metabolism. Increased risk of QTc prolongation and development arrhythmias. Concomitant use is contraindicated. (source: Drug Bank )
voriconazole - pipotiazine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of pipotiazine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of pipotiazine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - piroxicam Piroxicam, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if piroxicam is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - prazepam Voriconazole may increase the serum concentration of prazepam by decreasing its metabolism. Monitor for prazepam toxicity if voriconazole is initiated or dose increased. (source: Drug Bank )
voriconazole - praziquantel Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of praziquantel by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of praziquantel if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - probucol Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - procainamide Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - propafenone Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - protriptyline Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - quetiapine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of quetiapine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of quetiapine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - quinidine Voriconazole may increase the serum concentration of quinidine likely by inhibiting its metabolism by CYP3A4. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the serum concentration and toxic effects of quinidine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - quinine Additive QTc prolongation may occur. Concomitant therapy should be avoided. (source: Drug Bank )
voriconazole - ranolazine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of ranolazine by decreasing its metabolism. Additive QTc prolongation may also occur. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - repaglinide Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of repaglinide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of repaglinide if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - rifabutin Rifabutin may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifabutin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - rifampin Rifampin may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifampin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - rifapentine Rifapentine may decrease the serum concentration of voriconazole likely by increasing its metabolism via CYP3A enzymes. Voriconazole may increase the serum concentration of rifapentin likely by inhibiting its metabolism via CYP3A. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - risperidone Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - ritonavir Ritonavir may decrease the serum concentration of voriconazole by increasing its metabolism. Concomitant therapy with high dose ritonavir is contraindicated. Caution should be used with lower doses as decreased voriconazole efficacy may occur. (source: Drug Bank )
voriconazole - salmeterol Voriconazole, a strong CYP3A4 inhibitor may increase the serum concentration of salmeterol by decreasing its metabolism. Consider alternate therapy. (source: Drug Bank )
voriconazole - saquinavir Voriconazole may increase the serum concentration of saquinavir by decreasing its metabolism. Saquinavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed. (source: Drug Bank )
voriconazole - sibutramine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sibutramine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sibutramine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - sildenafil Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sildenafil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sildenafil if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - simvastatin Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of simvastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastain if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - sirolimus Voriconazole may increase the serum concentration of sirolimus likely by inhibition of CYP3A4-mediated metabolism or p-glyprotein transport of sirolimus. Consider alternate therapy or reduce the dose of sirolimus and monitor serum levels during concomitant therapy. (source: Drug Bank )
voriconazole - solifenacin Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of solifenacin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of solifenacin if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - sotalol Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - sparfloxacin Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - sufentanil Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sufentanil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of sufentanil if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - sulfisoxazole Sulfisoxazole, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if sulfisoxazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - sunitinib Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of sunitinib by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of sunitinib if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - tacrolimus Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tacrolimus by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of tacrolimus if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - tadalafil Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tadalafil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tadalafil if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - tamoxifen Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tamoxifen by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tamoxifen if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - tamsulosin Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tamsulosin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tamsulosin if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - telithromycin Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of telithromycin by decreasing its metabolism. Telithromycin may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or dose changed. QTc interval prolongation may also occur. (source: Drug Bank )
voriconazole - temsirolimus Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of temsirolimus and its active metabolite, sirolimus, by decreasing their metabolism. Monitor for changes in the therapeutic and adverse effects of temsirolimus if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - teniposide Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of teniposide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of teniposide if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - tetrabenazine Additive QTc prolongation may occur. Concomitant therapy should be avoided. (source: Drug Bank )
voriconazole - theophylline Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of theophylline by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of theophylline if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - thioridazine Additive QTc prolongation may occur. Concomitant use is contraindicated. (source: Drug Bank )
voriconazole - thiothixene Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - tiagabine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tiagabine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tiagabine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - tipranavir Voriconazole may increase the serum concentration of tipranavir by decreasing its metabolism. Tipranavir may increase the serum concentration of voriconazole. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed. (source: Drug Bank )
voriconazole - tolbutamide Tolbutamine, a strong CYP2C9 inhibitor, may increase the serum concentration of voriconazole by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of voriconazole if tolbutamide is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - tolterodine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tolterodine by decreasing its metabolism. Tolterodine is mainly metabolized via the CYP2D6 pathway. This interaction is likely only a concern in patients who are poor CYP2D6 metabolizers. Monitor for changes in the therapeutic and adverse effects of tolterodine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - toremifene Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - tramadol Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of tramadol by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of tramadol if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - trazodone Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of trazodone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of trazodone if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - triazolam Voriconazole may increase the serum concentration of triazolam by decreasing its metabolism. Monitor for triazolam toxicity if voriconazole is initiated or dose increased. (source: Drug Bank )
voriconazole - trimipramine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of trimipramine by decreasing its metabolism. Additive QTc prolongation may also occur. Monitor for changes in the therapeutic and adverse effects of trimipramine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - vardenafil Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of vardenafil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of vardenafil if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - venlafaxine Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of venlafaxine by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of venlafaxine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - verapamil Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of verapamil by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of verapamil if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - vinblastine Voriconazole may increase the serum concentration and toxicity of vinblastine. Adjust dose of vinblastine and monitor for changes in the therapeutic and adverse effects of vinblastine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - vincristine Voriconazole may increase the serum concentration and toxicity of vincristine. Adjust dose of vinblastine and monitor for changes in the therapeutic and adverse effects of vincristine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - vinorelbine Voriconazole may increase the serum concentration and toxicity of vinorelbine. Adjust dose of vinorelbine and monitor for changes in the therapeutic and adverse effects of vinorelbine if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - vorinostat Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
voriconazole - ziprasidone Additive QTc prolongation may occur. Concomitant therapy is contraindicated. (source: Drug Bank )
voriconazole - zolpidem Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of zolpidem if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - zonisamide Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of zonosamide if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - zopiclone Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of zopiclone if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - zuclopenthixol Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
vorinostat - voriconazole Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
ziprasidone - voriconazole Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated. (source: Drug Bank )
zolpidem - voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
zonisamide - voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
zopiclone - voriconazole Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
zuclopenthixol - voriconazole Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )

Curated Information ?

EvidenceDisease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Carcinoma, Squamous Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cystic Fibrosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Drug Toxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Granulomatous Disease, Chronic
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hematologic Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
hematopoietic stem cell transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
hemopoietic stem cell transplant
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Hepatitis C
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Infection
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
lung transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lymphoma
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Mycoses
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Precursor Cell Lymphoblastic Leukemia-Lymphoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Severe Combined Immunodeficiency
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Shock, Septic
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Toxic liver disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
treatment failure

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to voriconazole: 73

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: voriconazole pathway, pharmacokinetics. Pharmacogenetics and genomics. 2017. Barbarino Julia M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole. Clinical pharmacology and therapeutics. 2017. Walsh T J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Auto-inhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics. British journal of clinical pharmacology. 2017. Hohmann Nicolas, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections. Pharmacogenetics and genomics. 2017. Hamadeh Issam S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of voriconazole: CYP2C19 but also CYP3A4 need to be genotyped. Clinical pharmacology and therapeutics. 2017. Gautier-Veyret Elodie, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report. Journal of cancer research and clinical oncology. 2017. Beata Sienkiewicz, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guideline for CYP2C19 and Voriconazole Therapy. Clinical pharmacology and therapeutics. 2016. Moriyama Brad, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of Cytochrome P450 3A4 and non-genetic factors on initial Voriconazole serum trough concentrations in Hematological Patients with different Cytochrome P450 2C19 genotypes. Xenobiotica; the fate of foreign compounds in biological systems. 2016. Shao Beibei, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis. European journal of clinical pharmacology. 2016. Li Xiaofei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects. Journal of clinical pharmacology. 2016. Zhu Li, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit. Pharmacotherapy. 2016. Wang Yan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations. Pharmacogenomics. 2016. Hicks J Kevin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of CYP2C19 *17/*17 Genotype With the Risk of Voriconazole-Associated Squamous Cell Carcinoma. JAMA dermatology. 2016. Williams Kiyanna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The Effect of Genetic Polymorphism on the Inhibition of Azole Antifungal Agents Against CYP2C9-Mediated Metabolism. Journal of pharmaceutical sciences. 2016. Niwa Toshiro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Invasive aspergillosis in a paediatric allogeneic stem cell transplantation recipient owing to a susceptible Aspergillus fumigatus: Treatment failure with high doses of voriconazole and influence of CYP2C19 polymorphisms. International journal of antimicrobial agents. 2016. Cendejas-Bueno Emilio, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A prospective observational study of CYP2C19 polymorphisms and voriconazole plasma level in adult Thai patients with invasive aspergillosis. Drug metabolism and pharmacokinetics. 2016. Sumonrat Chuwongwattana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. International journal of antimicrobial agents. 2015. Lamoureux Fabien, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomically actionable medications in a safety net health care system. SAGE open medicine. 2016. Carpenter Janet S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genotype - Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2015. Teusink A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Is your love in vain? On associations between genotypes, drug concentrations and clinical outcomes in pharmacogenomic research. International journal of clinical pharmacy. 2015. Damkier Per. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gain-of-function single nucleotide variants of the CYP2C19 gene (CYP2C19*17) can identify subtherapeutic voriconazole concentrations in critically ill patients: a case series. Intensive care medicine. 2015. Weigel Joachim D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of Cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole. Journal of clinical pharmacology. 2015. Imamura Chiyo K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype. British journal of clinical pharmacology. 2015. Bennis Youssef, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19*17 genetic polymorphism-an uncommon cause of voriconazole treatment failure. Diagnostic microbiology and infectious disease. 2015. Abidi Maheen Z, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians. International journal of clinical pharmacy. 2015. Chawla Prerna K, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2015. He H-R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort. The Journal of antimicrobial chemotherapy. 2015. Trubiano J A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients. Antimicrobial agents and chemotherapy. 2015. Mori Masaaki, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles. Drug design, development and therapy. 2015. Chung Hyewon, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. International journal of antimicrobial agents. 2014. Wang Taotao, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of antimicrobial agents. Pharmacogenomics. 2014. Aung Ar Kar, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. Pharmacogenomics. 2014. Calcagno Andrea, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. Pharmacogenomics. 2014. Hicks J Kevin, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. The Journal of infectious diseases. 2014. Zonios Dimitrios, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The genetics of pro-arrhythmic adverse drug reactions. British journal of clinical pharmacology. 2014. Petropoulou Evmorfia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?. Pharmacotherapy. 2014. Owusu Obeng Aniwaa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. The Journal of antimicrobial chemotherapy. 2014. Dolton Michael J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
EMA Initiatives and Perspectives on Pharmacogenomics. British journal of clinical pharmacology. 2014. Ehmann Falk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. European journal of clinical pharmacology. 2014. Naidoo Panjasaram, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity. AIDS research and therapy. 2014. Bouatou Yassine, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population. Infection & chemotherapy. 2013. Kim Si-Hyun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Correlation of CYP2C19 Phenotype With Voriconazole Plasma Concentration in Children. Journal of pediatric hematology/oncology. 2013. Narita Atsushi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype. Pharmacotherapy. 2013. Moriyama Brad, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency. Pharmacogenomics. 2012. Autmizguine Julie, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine. British journal of clinical pharmacology. 2012. Malingré Mirte M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2011. Kim Si-Hyun, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction. Mycoses. 2011. Moriyama Brad, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group. Pharmacogenomics. 2011. Patterson Scott D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics. 2011. Mikus Gerd, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Voriconazole toxicity related to polymorphisms in CYP2C19. Internal medicine journal. 2011. Suan D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics: From Bench to Byte- An Update of Guidelines. Clinical pharmacology and therapeutics. 2011. Swen J J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. European journal of clinical pharmacology. 2011. Berge Maud, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers. Journal of clinical pharmacology. 2011. Lee Seunghwan, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Therapeutic drug monitoring. 2011. Hassan Arwa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. European journal of clinical pharmacology. 2010. Shi Hui-Yan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. British journal of clinical pharmacology. 2010. Li-Wan-Po Alain, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. The Journal of antimicrobial chemotherapy. 2010. Brüggemann Roger J M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. British journal of clinical pharmacology. 2009. Scholz Ina, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. International journal of antimicrobial agents. 2009. Matsumoto Kazuaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADME pharmacogenetics: current practices and future outlook. Expert opinion on drug metabolism & toxicology. 2009. Grossman Iris. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. The Annals of pharmacotherapy. 2009. Lei He-Ping, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. European journal of clinical pharmacology. 2009. Wang Guo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. Journal of clinical pharmacology. 2009. Weiss Johanna, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clinical pharmacology and therapeutics. 2008. Hynninen V-V, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanyl. European journal of clinical pharmacology. 2008. Saari Teijo I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clinical pharmacokinetics. 2008. Nivoix Yasmine, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. The Journal of antimicrobial chemotherapy. 2007. Levin Mark-David, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clinical pharmacology and therapeutics. 2006. Saari Teijo I, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clinical pharmacology and therapeutics. 2006. Mikus Gerd, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clinical pharmacology and therapeutics. 2005. Rengelshausen Jens, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clinical pharmacology and therapeutics. 2004. Ikeda Yasuhiko, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0049-3190-28
DrugBank:
DB00582
ChEBI:
10023
KEGG Compound:
C07622
KEGG Drug:
D00578
PubChem Compound:
71616
PubChem Substance:
213886
46506421
Drugs Product Database (DPD):
2256460
ChemSpider:
64684
Therapeutic Targets Database:
DAP001271
FDA Drug Label at DailyMed:
ce3ef5cf-3087-4d92-9d94-9eb8287228db

Clinical Trials

These are trials that mention voriconazole and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.